Search

Displaying results 3381 - 3390 of 4262 in total
  1. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.

  2. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.

  3. Drug

    CLX-0921

    go.drugbank.com/drugs/DB05854
    Experimental

    It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to insulin.

  4. Drug

    BW-A 58C

    go.drugbank.com/drugs/DB06740
    Experimental

    naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by

  5. Drug

    Taspoglutide

    go.drugbank.com/drugs/DB14027
    Investigational

    Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.

  6. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]

  7. Drug

    CIGB 2020 Vaccine

    go.drugbank.com/drugs/DB15808
    Experimental

    The vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba.

  8. Drug

    Adlinacogene civaparvovec

    go.drugbank.com/drugs/DB16788
    Investigational

    [L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia B.[L46706]

  9. Drug

    Luvometinib

    go.drugbank.com/drugs/DB21696
    Investigational

    Luvometinib is under investigation in clinical trial NCT07004075 (FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration).

  10. Drug

    Glypromate

    go.drugbank.com/drugs/DB05633
    Experimental

    glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for the potential treatment of neurodegenerative diseases by